论文部分内容阅读
目的:探讨紫杉醇联合卡铂治疗局部晚期乳腺癌的临床疗效和安全性。方法:选取2010年3月~2012年8月在我院接受治疗的局部晚期乳腺癌患者80例,以其中采用紫杉醇联合卡铂治疗的40例患者作为实验组,紫杉醇联合表阿霉素治疗的40例患者作为对照组,化疗后患者行乳腺癌改良根治术或保乳术,观察和比较两组患者的治疗有效率、不良反应的发生情况及术后复发和转移情况。结果:两组患者的治疗有效率及不良反应的发生率比较均并无统计学差异(P>0.05),而实验组患者术后复发及转移的发生率明显低于对照组患者(P<0.05)。结论:紫杉醇联合卡铂治疗局部晚期乳腺癌的临床疗效及安全性与紫杉醇联合表阿霉素化疗相当,但是能够明显降低患者的术后复发率及转移率,改善患者的预后。
Objective: To investigate the clinical efficacy and safety of paclitaxel combined with carboplatin in the treatment of locally advanced breast cancer. Methods: Eighty patients with locally advanced breast cancer treated in our hospital from March 2010 to August 2012 were enrolled in this study. Forty patients with paclitaxel plus carboplatin were enrolled as experimental group. Paclitaxel combined with epirubicin Forty patients were used as control group. After chemotherapy, the patients underwent modified radical mastectomy or breast-conserving surgery. The treatment efficiency, the incidence of adverse reactions, and the recurrence and metastasis of the two groups were observed and compared. Results: There was no significant difference between the two groups in the treatment efficiency and the incidence of adverse reactions (P> 0.05), while the incidence of postoperative recurrence and metastasis in the experimental group was significantly lower than that in the control group (P <0.05 ). Conclusion: The clinical efficacy and safety of paclitaxel combined with carboplatin in the treatment of locally advanced breast cancer are comparable with paclitaxel and epirubicin chemotherapy, but can significantly reduce the postoperative recurrence rate and metastasis rate and improve the prognosis of patients with locally advanced breast cancer.